Business Context and Reporting Period
This Form 8-K was filed by Seneca Biopharma, Inc. (trading symbol: SNCA) on April 7, 2020, reporting an event that occurred on April 3, 2020. The filing details an amendment and restatement of the Company's non-employee Board of Directors compensation policy, effective April 1, 2020.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on governance and compensation adjustments.
Material Changes
The primary material change is the restructuring of non-employee director compensation for the Board Year commencing April 1, 2020. Key components of the new policy include:
- Equity Grant: Each non-employee director receives 6,000 restricted stock units (RSUs) granted on April 3, 2020, and annually thereafter. These vest quarterly on June 30, September 30, December 31, and March 31.
- Base Cash Fee: An annual cash fee of $40,000 per director, paid in arrears quarterly.
- Committee Fees: Additional annual fees for committee service:
- Lead Independent Director: $25,000
- Audit Committee Member: $10,000
- Compensation Committee Member: $7,500
- Governance and Nominating Committee Member: $5,000
- Chairperson Fees: Additional annual fees for chairing committees:
- Audit Committee Chair: $10,000
- Compensation Committee Chair: $7,500
- Governance and Nominating Committee Chair: $5,000
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of risks and contingencies. It is a procedural disclosure regarding executive compensation.
Investor Verification Checklist
- Verify the total number of non-employee directors to calculate the aggregate cash and equity cost of the new policy.
- Confirm the specific equity compensation plan from which the 6,000 RSUs per director are being issued.
- Review the Company's cash position to ensure it can support the increased quarterly cash outflows for director fees.
- Check for any prior compensation policies to quantify the exact increase in total director compensation.